Drug Profile
Purine nucleoside phosphorylase gene therapy - GeoVax Labs/PNP Therapeutics
Alternative Names: Ad/PNP; Ad/PNP/F-araAMP; Adenovirus/PNP; GedeptinLatest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator Southern Research Institute; University of Alabama
- Developer PNP Therapeutics
- Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Squamous cell cancer
- Phase Unknown Pharyngeal neoplasms
Most Recent Events
- 22 Jan 2024 GeoVax Labs completes enrolment in a phase I/II trial in Squamous cell cancer (Late-stage disease, Metastatic-disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural) before January 2024 (NCT03754933) (GeoVax Labs pipeline, January 2024)
- 10 Jul 2023 Adverse events and efficacy data from a phase I/II trial in Squamous cell cancer released by GeoVax Labs
- 01 Mar 2023 Phase I/II development is ongoing in USA for Squamous cell cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater)